6
Participants
Start Date
February 28, 2006
Primary Completion Date
June 30, 2011
Study Completion Date
June 30, 2011
Capecitabine, Oxaliplatin and Cetuximab
Capecitabine 825mg/m2 po BID D1-15 of 21 x2 cycles (Cyle 1 and 2), Capecitabine 825mg/m2 po BID weekly Sun PM-Fri AM x2 cycles (cycle 3 and 4), Capecitabine 825mg/m2 po BID D1-15 of 21 x4 cycles (cycle 5,6,7,8) Oxaliplatin 130mg/m2 IV Day 1 every 3 weeks x2 cycles (Cycle 1 and 2), Oxaliplatin 50mg/m2 IV weekly every Monday x2 cycles (Cycle 3 and 4), Oxaliplatin 130mg/m2 IV day 1 every 3 weeks x4 cycles (Cycles 5,6,7,8) Cetuximab 400mg/m2 IV cycle 1 day1, Cetuximab 250mg/m2 Day 1,8,15 of 21 for cycles 1-8
Radiation
45 Gy in 25 fractions, 3-fraction boost 5.4 Gy
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Roche Pharma AG
INDUSTRY
Abramson Cancer Center at Penn Medicine
OTHER